Partners Amgen Inc. and Allergan plc said the phase III study of ABP 215 – a biosimilars candidate to Avastin (bevacizumab, Genentech Inc./Roche AG) and the first in the oncology collaboration to complete a late-stage trial – met its primary and secondary endpoints in comparing efficacy and safety to the reference drug in adults with advanced non-squamous non-small-cell lung cancer (NSCLC).